[HTML][HTML] Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: rationale and design of …
K Okumura, GYH Lip, M Akao, K Tanizawa… - American Heart …, 2017 - Elsevier
Edoxaban—a non–vitamin K antagonist oral anticoagulant (NOAC)—60-mg and 30-mg
once-daily dose regimens are noninferior versus well-managed warfarin for the prevention
of stroke or systemic embolic events (SEE) with less major bleeding in patients with
nonvalvular atrial fibrillation (NVAF). There are no published data from phase 3 clinical trials
specifically evaluating the use of NOACs in elderly NVAF patients, especially those
considered ineligible for available oral anticoagulants. The Edoxaban Low-Dose for EldeR …
once-daily dose regimens are noninferior versus well-managed warfarin for the prevention
of stroke or systemic embolic events (SEE) with less major bleeding in patients with
nonvalvular atrial fibrillation (NVAF). There are no published data from phase 3 clinical trials
specifically evaluating the use of NOACs in elderly NVAF patients, especially those
considered ineligible for available oral anticoagulants. The Edoxaban Low-Dose for EldeR …
以上显示的是最相近的搜索结果。 查看全部搜索结果